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Abstract
It is well established that RNA viruses exhibit higher rates of spontaneous mutation than DNA viruses and microorganisms.
However, their mutation rates vary amply, from 1026 to 1024 substitutions per nucleotide per round of copying (s/n/r) and
the causes of this variability remain poorly understood. In addition to differences in intrinsic fidelity or error correction
capability, viral mutation rates may be dependent on host factors. Here, we assessed the effect of the cellular environment
on the rate of spontaneous mutation of the vesicular stomatitis virus (VSV), which has a broad host range and cell tropism.
Luria-Delbru¨ck fluctuation tests and sequencing showed that VSV mutated similarly in baby hamster kidney, murine
embryonic fibroblasts, colon cancer, and neuroblastoma cells (approx. 1025 s/n/r). Cell immortalization through p53
inactivation and oxygen levels (1–21%) did not have a significant impact on viral replication fidelity. This shows that
previously published mutation rates can be considered reliable despite being based on a narrow and artificial set of
laboratory conditions. Interestingly, we also found that VSV mutated approximately four times more slowly in various insect
cells compared with mammalian cells. This may contribute to explaining the relatively slow evolution of VSV and other
arthropod-borne viruses in nature.
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Introduction
RNA viruses show extremely high genetic variability and rapid
evolution, ultimately due to their elevated rates of spontaneous
mutation, which range from 1026 to 1024 substitutions per
nucleotide per round of copying (s/n/r). However, mutation rate
estimates vary considerably, even for the same virus [1,2]. Since
viral mutation rates have implications for pathogenesis [3,4],
vaccine development [5,6] antiviral therapy [7,8], and epidemi-
ological disease management [9,10], it is important to have
accurate data and a clear understanding of the factors determining
these rates. As a case in point, the risk of cross-species transmission
is determined, in addition to the ecology of virus-host interactions,
by the input of new adaptive mutations in the viral population
[11], and a recent phylogenetic analysis of rabies virus isolates
suggested that the waiting time required for host jumps depends
on the number of positively selected mutations involved in cross-
species transmission [12].
In RNA viruses, mutation rates are determined by the intrinsic
base selection specificity of the viral polymerase [13–16], the
presence/absence of proofreading mechanisms such as 39exonu-
clease activity [17–19], or the mode of replication [20,21].
However, in addition to these virus-encoded factors, viral
mutation rates can be host-dependent. For instance, it has been
suggested that the replicase of cucumber mosaic virus exhibits
different fidelity in pepper and tobacco plants [22,23]. In
retroviruses, replication fidelity may be affected by intra-cellular
dNTP imbalance and total concentration, which vary among cell
types [24–26], although a recent study revealed no differences in
the HIV-1 mutation rate in various cell types including T
lymphoblast, glioblastoma and human embryonic kidney cells
[27]. Also, the expression of host genes may influence the viral
mutation rate as is the case of APOBEC3 cytidine deaminases,
which can edit the HIV-1 cDNA and produce G-to-A hypermuta-
tions [28–30]. A similar role was postulated for the cellular RNA-
dependent adenosine deaminase (ADAR) which could lead to A-
to-G hypermutation in several RNA viruses, including rhabdovi-
ruses [31], paramyxoviruses [32], and retroviruses [33–35].
Finally, cell metabolism may also have an impact in viral mutation
rates, since it has been shown that ethanol-derived reactive oxygen
species (ROS) can damage the RNA of hepatitis C virus, whereas
other compounds such as glutathione and iron chelators were
found to have the opposite effect [36].
Vesicular stomatitis virus (VSV) is a non-segmented negative-
stranded RNA virus belonging to the family Rhabdoviridae with an
extremely wide host tropism. The virion attaches to phosphadtidyl
serine or other ubiquitous cell surface receptors and can
productively infect most mammalian cells [37]. In nature, VSV
infects a very large number of mammal species including livestock
(cattle, horse, swine, goats, etc.) and wild animals (rodents, bear,
lynx, bats, etc.), and also infects insects (sandflies, blackflies,
mosquitoes, etc.) [38,39], which act as transmission vectors [40–
42]. Therefore, VSV replicates in widely different cellular
environments, but the impact of this heterogeneity on the viral
mutation rate is unknown. Actually, nearly all mutation rate
estimates for animal viruses have been obtained in standard
laboratory cell lines, which are usually immortalized or cancerous
and thus show aberrant metabolic/mitotic rates and gene
expression patterns. For VSV, most studies are conducted using
hamster kidney cells, despite the fact that the brain is the main
target organ of rhabdoviruses. Furthermore, all viral mutation rate
studies have been conducted under atmospheric oxygen levels but
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these are substantially higher than those found in most tissues [43],
and the impact of this type of environmental stress in the estimates
is unknown. Here, we measured the mutation rate of VSV in
primary and tumoral cell types including murine fibroblasts of
various origins and neural cells, and under different oxygen levels,
as well as insect cells. We found that the VSV mutation rate was
relatively constant in all mammalian cells tested. However, VSV
mutated four times more slowly in insect cells than in mammalian
cells, a finding that may have implications for our understanding
of arboviral evolution.
Results/Discussion
Fluctuation tests in BHK-21 cells
We measured the mutation rate of VSV by the Luria-Delbru¨ck
fluctuation test, a standard estimation method [44] that has been
used previously in several viruses including poliovirus [45], vesicular
stomatitis virus [46], influenza A virus [47], measles virus [48],
turnip mosaic virus [49], and bacteriophages w6 [20] and Qb [50].
To score mutants, we used a monoclonal antibody against the
envelope glycoprotein G and determined the probability of
appearance of monoclonal antibody resistance (MAR) mutants in
independent cultures (null-class method). First, we performed six
independent tests in baby hamster kidney cells (BHK-21), for
which we had previous results [46]. This gave an average mutation
rate to the MAR phenotype of m= (1.6460.27)61025 per
round of copying (Table 1). This rate can be converted to per-
nucleotide units as m~3m=T , where T is the set of observable
mutations leading to the phenotype (mutation target) and three
stands for the number of possible nucleotide substitutions per site
[2]. Sequencing of the glycoprotein G gene from 15 MAR plaques
allowed us to identify four different nucleotide substitutions, which
led to amino acid changes D257N, D259A, D259N, and S273T,
whereas previous work reported the same substitutions at position
259 of the G glycoprotein in addition D257G, D257V, D257Y and
A263E [51]. Taking T= 8, the estimated mutation rate is
m= 6.1561026 substitutions per nucleotide per round of copying
(s/n/r).
Validation by molecular clone sequencing
To verify the reliability of the above estimate, we used a
molecular clone sequencing approach. This allowed us to score
mutations more directly than in fluctuation tests and to analyze a
wider genome region, although the interpretation of the data is
complicated by the fact that the observed mutation frequency is
dependent on selection, the number of generations elapsed, etc.
BHK-21 cells were infected with a single infectious particle (i.e.
plaque forming unit, pfu) by limiting dilution, and the resulting viral
bursts (1.556107 final pfu on average) were used for RNA
purification, RT-PCR, molecular cloning, and sequencing of three
genome regions mapping to genes P, G, and L. We observed four
single-nucleotide substitutions in 77500 bases in total, giving a
mutation frequency of f= 5.1661025 (Table 2). For a per-cell burst
size of B= 1250 [46], the number of infection cycles (i.e. viral
generations) elapsed should be c~
ln 1:55|107
ln 1250
~2:3. Therefore,
the per-generation increase in mutation frequency was
f =c~2:24|10{5. To account for the effect of selection, we used
the previously characterized distribution of mutational fitness effects
(see Methods). Based on this, the expected fraction of observable
mutations after 2.3 generations was 53% and, thus, the estimated
per-cell mutation rate is mc~
f
ca
~4:23|10{5. The exact number
of round of copying per cell is unknown but a previous work
suggested rC = 5.8 rounds/cell, implying that m= 7.30610
26 s/n/r.
This estimate is fully consistent with the results provided by the
Luria-Delbru¨ck fluctuation test. Subsequent experiments were done
Author Summary
RNA viruses show high rates of spontaneous mutation, a
feature that profoundly influences viral evolution, disease
emergence, the appearance of drug resistances, and
vaccine efficacy. However, RNA virus mutation rates vary
substantially and the factors determining this variability
remain poorly understood. Here, we investigated the
effects of host factors on viral replication fidelity by
measuring the viral mutation rate in different cell types
and under various culturing conditions. To carry out these
experiments we chose the vesicular stomatitis virus (VSV),
an insect-transmitted mammalian RNA virus with an
extremely wide cellular and host tropism. We found that
the VSV replication machinery was robust to changes in
cellular physiology driven by cell immortalization or shifts
in temperature and oxygen levels. In contrast, VSV
mutated significantly more slowly in insect cells than in
mammalian cells, a finding may help us to understand why
arthropod-borne viruses tend to evolve more slowly than
directly transmitted viruses in nature.
Table 1. Fluctuation tests of VSV in BHK-21 cells.
Test 1 Test 2 Test 3 Test 4 Test 5 Test 6
Ni (pfu) 160611 267618 3586114 355635 293636 290610
Nf (pfu) 2456261021 108756956 203756849 3815061590 4615761044 172006934
Total cultures 24 24 24 24 24 24
With no MAR 16 20 17 16 16 15
With 1 MAR 6 4 6 7 7 4
With 2 MARs 0 0 1 1 0 2
With .2 MARs 2 0 0 0 1 3
Fraction with no MAR (P0) 0.667 0.833 0.708 0.667 0.667 0.625
Mutation rate (m) 1.6661025 1.7161025 1.7261025 1.0761025 0.8861025 2.7861025
doi:10.1371/journal.ppat.1003855.t001
Viral Mutation
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using fluctuation tests only because they provided a faster and
simpler approach.
Constant mutation rate in mammalian cells
Previous mutation rate studies with VSV have been conducted
in BHK-21 cells only [2,46,52]. However, these are immortal-
ized/tumoral cells, as opposed to those typically encountered
bythe virus in vivo. Furthermore, VSV has a tropism for neural
cells, and kidney fibroblasts are not a natural target of the virus.
Toaddress the potential effect of immortalization on the viral
mutation rate, we performed fluctuation tests in primary mouse
embryonic fibroblasts (MEFs) and isogenic, p53 knock-out, MEFs.
The average rate was similar in normal (m= 1.2761025) and
p53knock-out MEFs (m= 0.8261025), revealing no significant
effectof cellular immortalization (Figure 1; t-test: P= 0.232, n= 6).
However, many cell lines are tumoral and show other genetic
andmetabolic alterations in addition to p53 inactivation. To check
the potential effects of these changes, we performed fluctuation tests
in CT26 cells from an undifferentiated grade IV colon adenocar-
cinoma of a BALB/c mouse [53], but we found no significant
differences with primary MEFs (m= 1.1861025; t-test: P= 0.885,
n= 6). Of note, BHK-21 are also tumor-forming cells, and the
mutation rate was similar to the rate observed in MEFs or CT26
cells (one-way ANOVA: P= 0.293, n= 12). This homogeneity in the
VSV mutation rate was not an obvious a priori, because metabolic
and mitotic activity should alter the availability of NTPs [54] and
hence could impact RNA replication fidelity, although VSV
replicates in the cytoplasm and may not be strongly affected by
these alterations. This result has implications for the field of
oncolytic virotherapy [55], since it is critical to assess the genetic
stability of these therapeutic viruses during large-scale manufactur-
ing and clinical use. In particular, CT26 cells have been used in
mice as a model for testing the oncolytic activity of VSV [56]. Also,
the above results suggest that VSV replicates with similar fidelity in
different cell types, but we sought to test whether this would also
hold for neural cells. We therefore performed fluctuation tests in
Neuro-2a cells from a mouse neuroblastoma [57]. Again, we found
that the average mutation rate did not significantly differ from the
rate obtained in BHK-21 cells (m= 1.0661025; t-test: P= 0.461,
n= 9). Finally, to test for other potential effects of cell physiology, we
also varied oxygen levels. The VSV mutation rate in BHK-21 cells
cultured under hypoxic conditions (1% oxygen) was slightly higher
but not significantly different to the rate obtained under standard
conditions (m= 2.7161025; t-test: P= 0.122, n= 9). Oxidative stress
should lead to the release of ROS, which have been previously
shown to be mutagenic for hepatitis C virus [36]. However, VSV
does not appear to be sensitive to oxidation levels. This might be
related to the fact that the nucleocapsid of mononegavirales forms a
tunnel-like structure which wraps the viral genomic RNA and
remains assembled during the entire infection cycle [58,59],
effectively isolating the viral RNA [60].
Lower mutation rate in insect cells
Since VSV alternates between mammalian and insect hosts in
nature, we sought to measure the viral mutation rate in insect
cells (Figure 1). In S2 cells from D. melanogaster embryos, the
average estimate from three independent fluctuation tests was
m = 4.0861026, representing a fourfold decrease compared with
BHK-21 (t-test: P = 0.009, n = 9). To further investigate this, we
selected two additional insect cells lines: Sf21 ovarian cells from
the moth Spodoptera frugiperda, and C6/36 from Aedes albopictus
mosquito larvae. Also, since insect cells were infected at 28uC and
mammalian cells at 37uC, we performed four additional tests in
BHK-21 at 28uC. We used estimates obtained in mammalian
(BHK-21, BHK-21 at 28uC, MEF, MEF p532/2, CT26, and
Neuro-2a) and insect cells (S2, Sf-21, and C6/36) to jointly test
for the effects of host type and temperature (fixed factors) in a
two-way ANOVA in which the specific cell line was treated as a
random factor nested within host type. This confirmed that VSV
shows lower mutation rate in insect cells than in mammalian cells
(ANOVA: P,0.001), and also that temperature cannot account
for this result because the estimates in BHK-21 were actually
higher at 28uC than at 37uC (P = 0.001). Using log10-transformed
Table 2. Molecular clone sequencing of VSV from BHK-21 cells.
Gene P G L
Genome sites 1339–1899 3858–4347 6974–7462
Clones sequenced 50 50 50
Total bases read 28050 25000 24450
Mutations A1821C (LysRThr) G1640A (GlyRArg) A3983G (GluRGlu) T3937A (LeuRHis) None
doi:10.1371/journal.ppat.1003855.t002
Figure 1. VSV mutation rate to the MAR phenotype estimated
by the Luria-Delbru¨ck fluctuation test in different cellular
environments. Each dot represents an independent estimate (n=3
for all except n=6 for BHK-21 and n= 4 for BHK-21 at 28uC). Horizontal
bars indicate the mean rate. Detailed information for each test is
provided in Table 1 and in Text S1.
doi:10.1371/journal.ppat.1003855.g001
Viral Mutation
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data, the estimated effect size of the host type in the above model
was 0.59060.205, which implies a 3.9 fold mutation rate
decrease in insect cells. One possible explanation for this
difference is that our sensitivity to detect MAR mutants varied
between assays performed in mammalian and insect cells. To
address this, we first verified that MAR plating efficiency was
similar in BHK-21, S2, Sf21, and C6/36 cells using a genetically
engineered MAR mutant (D259A). Second, we tested for
differences in the mutation target size (T). To do this, we
sampled 15 individual MAR plaques from fluctuation tests
performed in S2 cells and sequenced the region of the G protein
controlling this phenotype. We found the same amino acid
replacements as in fluctuation tests performed in BHK-21 cells
(D257N, D259N, S273T, see above) except for D259A.
However, because the D259 mutant is viable in insect cells
[61], failure to detect it was probably due to insufficient sampling
depth. We also found substitution A263E, which was reported
previously in BHK-21 cells [51]. Therefore, insect S2 and BHK-
21 cells shared a similar mutational repertoire and plating
efficiency, supporting the consistency of the observed mutation
rate difference. Interestingly, VSV [62] and arboviruses in
general [63,64] tend to evolve more slowly than directly
transmitted viruses. Our own meta-analysis using 170 previously
published evolutionary rates confirmed that, after accounting for
phylogenetic relatedness and the timespan of sequence sampling,
arboviruses showed a significantly lower evolution rate than
directly transmitted viruses (Figure 2; two-way ANOVA:
P = 0.006), the geometric mean rates being 5.761024 substitu-
tions per site per year (s/s/y) and 1.361023 s/s/y, respectively.
This has been often interpreted in terms of fitness tradeoffs,
whereby neutral or beneficial mutations in mammals can be
deleterious in insects, and vice versa, thus restricting viral
evolution. However, whether arboviruses show similar mutation
rates in mammalian and insect cells has not been addressed
before, and our results offer a new possible explanation for the
relatively slow arboviral evolution. Future experiments with other
arboviruses could help elucidate the generality of these findings
and, if so, to delineate the mechanisms behind the observed
differences in replication fidelity.
Materials and Methods
Virus
Viruses were obtained from an infectious cDNA clone by
transfecting baby hamster kidney (BHK-21) cells [65,66], purified
by filtration (0.22 mm), and stored at 70uC in aliquots until use.
Cell culturing
BHK-21 cells (American Type Culture Collection, ATCC) were
cultured in DMEM supplemented with 10% fetal bovine serum
(FBS), 0.02 mM L-Glutamine, a mix of non-essential amino-acids,
100 mg/mL streptomycin, 60 mg/mL penicillin, and 2 mg/mL
fungizone. MEFs and their p532/2 derivatives were obtained
from Dr. Carmen Rivas (Centro Nacional de Biotecnologı´a,
Madrid) and cultured in the same medium but with 12% FBS.
Neuro-2a cells were obtained from Prof. Jose´ M. Garcı´a-Verdugo
(Department of Cell Biology, University of Valencia) and cultured
in MEM supplemented with 2 mM L-Glutamine, 1 mM sodium
pyruvate, 10% FBS, non-essential amino acids and the above
antibiotics. CT26 cells (ATCC) were cultured in DMEM with
10% FBS, 2 mM L-glutamine, 10 mM HEPES and antibiotics.
All the above cells were incubated at 37uC with 5% C02 and
passaged upon confluence. D. melanogaster Schneider (S2) cells were
obtained from Dr. Rube´n Artero (Department of Genetics,
University of Valencia) and cultured in Schneider’s medium
supplemented with 10% FBS and antibiotics at 25uC in the
absence of C02, and infected at 28uC. Sf21 cells were obtained
from Dr. Salvador Herrero (Department of Genetics, University of
Valencia) and were cultured in Grace’s insect medium supple-
mented with 10% FBS and antibiotics at 28uC in the absence of
C02. C6/36 cells (ATCC) were cultured in DMEM supplemented
with 10% FBS, 2 mM L-glutamine, non-essential amino acids,
1 mM sodium pyruvate and antibiotics at 28uC under 5% C02.
Hypoxia was achieved by displacing oxygen with nitrogen, using a
Galaxy 170R incubator (Eppendorf).
Luria-Delbru¨ck fluctuation tests
We inoculated 32 identical cultures each containing 104
confluent cells with approximately 300 pfu/well (Ni) and incubat-
ed them until approximately 36104 pfu/well were produced (Nf).
After a round of freeze-thawing to release intracellular particles,
we used eight cultures for titration and 24 for plating the entire
undiluted volume (100 mL) in the presence of a monoclonal
antibody against the surface glycoprotein G at a concentration that
neutralizes completely the wild-type virus and selects for MAR
mutants. The antibody, in the form of a hybridoma supernatant,
was added to the plating medium (25% v:v) to avoid phenotypic
masking [52]. Plating assays were done in DMEM gelled with
0.4% agarose containing 2% FBS. After 24 h, monolayers were
fixed with 10% formaldehyde and stained with 2% crystal violet to
visualize plaques. Since mutation is a rare event, the number of
mutations per culture is expected to follow a Poisson distribution
of parameter l~m(Nf{Ni) and therefore the probability of
observing no mutants in a culture is P0~e
{m(Nf{Ni), where m is
the mutation rate from the wild-type to the MAR phenotype (null-
class method). However, if there is incomplete plating, some
cultures may contain undetected MAR mutants. If we define z as
the plating efficiency (relative to BHK-21 cells), the probability of
observing no mutants can be expressed as P0~
P
kQk(1{z)
k,
where Qk is the probability of k actual mutants in a culture. Using
Figure 2. Molecular evolution of directly transmitted and
arthropod-transmitted riboviruses. Data were collected from the
supplementary information of a previous meta-analysis [69] and include
170 evolutionary rates, 113 for directly transmitted viruses and 57 for
arboviruses. The box plot indicates the median (central lines),
percentiles 25/75 (box) and percentiles 10/90 (bars), and outliers (dots).
doi:10.1371/journal.ppat.1003855.g002
Viral Mutation
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a Poisson distribution of parameter l~m(Nf{Ni) for k, we
numerically solved Q0 given P0, Ni, Nf, and z and calculated the
mutation rate as m~{ ln(Q0)=(Nf{Ni).
Plating efficiency in fluctuation tests
For each cell type tested, the plaque assay for scoring MAR
mutants was done in BHK-21 cells for technical feasibility and to
control for differences in plating efficiency among cells. However,
since plaque assays to score MAR mutants were done without
dilution, antiviral cytokines or other compounds released from the
cells in which the virus was grown could modify plating efficiency
(plaque assays for determining Nf were done at a roughly 1/100
dilution and thus were much less affected by this problem). For
instance, BHK-21 cells are at least partially responsive to interferon
[67], potentially inhibiting growth of MAR mutants and biasing
mutant counts down. To calibrate this effect, we titrated a MAR
clone obtained by site-directed mutagenesis (substitution D259A in
the surface glycoprotein G) in the presence of undiluted superna-
tants harvested from cells previously infected with the wild-type
virus (Ni<300 pfu and Nf><104 pfu, similar to fluctuation tests),
adding monoclonal antibody to the plates to observe MAR plaques
only. The wild-type infections were performed under each of the
experimental conditions (BHK-21, MEF, MEF p532/2, CT26,
Neuro-2a, BHK-21 with 1% O2, BHK-21 at 28uC, S2, Sf21 and
C6/36 cells). Addition of supernatants from BHK-21 cells infected
under standard conditions did not alter the titer of the D259 MAR
clone, hence the relative plating efficiency was z= 1. The relative
plating efficiency for each of the other conditions is shown in the
Supporting Information ‘‘Text S1’’ and was based on at least six
independent plating assays.
Mutation target size in fluctuation tests
To ascertain the number of possible mutations conferring the
MAR phenotype, we plated approximately 105 pfu in the presence
of antibody, incubated them for 24 h, and pipetted individual
plaques. Viral RNA was purified, reverse-transcribed using
AccuScript High Fidelity Reverse Transcripatse (Agilent Tech-
nologies), and the cDNA was PCR-amplified using Phusion High
Fidelity DNA polymerase (New England Biolabs). We used specific
primers to amplify and sequence a region of the G protein
(genome sites 3361 to 4501 in GenBank accession EF197793)
which controls the MAR phenotype [51]. PCR products were
sequenced by the Sanger method and analyzed using Staden
software.
Mutation frequency determination by molecular clone
sequencing
A 96-well plate containing 104 cells per well was inoculated with
a limiting dilution of the viral stock such that approximately 10%
of wells were infected. Plates were incubated at 37uC for 24 h,
inspected under the microscope for cytopathic effects, and freeze-
thawed to allow release of intracellular viruses. Viral RNA was
purified from the supernatant of each of five positive wells and
reverse-transcribed using AccuScript High Fidelity Reverse
Transcripatse, and the cDNA was PCR-amplified using Phusion
High Fidelity DNA polymerase and specific primers located in the
P, G and L genes, as indicated. PCR products were cloned and
used for E.coli transformation, and 10 colonies were picked and
amplified by colony PCR using Phusion High Fidelity DNA
polymerase. PCR products were sequenced by the Sanger method
and analyzed using Staden software. To obtain the mutation
frequency, the number of observed mutations was divided by the
total number of bases sequenced.
Effect of selection on mutation frequency
We used the empirically characterized distribution of muta-
tional fitness effects of random single-nucleotide substitutions in
VSV to correct for the effect of selection on mutation frequency
and obtain the mutation rate per cell infection. We did so
numerically by simulating the combined effects of mutation and
selection. The statistical distribution of fitness effects (s) for viable
substitutions can be roughly captured using an exponential
distribution truncated at s~1 (lethality) plus a class of lethals
occurring with probability pL: P(s)~(1{pL)
le{ls
1{e{l
if 0,s,1,
p(s)~pL if s= 1, and p(s)~0 otherwise. In a previous work using
the same VSV strain as here, it was estimated that pL~0:40 and
that E(s)~
1
l
~0:13 [65,68]. Fitness effects were measured as
growth rate ratios, si~1{
ri
r0
, where r is the exponential growth
rate and subscripts i and 0 refer to the mutant and wild-type,
respectively [65]. These s-values were transformed to per cell
infection units as si
’~1{
B1{si{1
B{1
, where B is the burst size.
After simulating fitness effects using the truncated exponential plus
lethal distribution and applying the per cell infection transforma-
tion, selection was applied by picking individuals for the next cell
infection cycle with weighted probability 12s9, and the process
was iterated. This provided an expected mutation frequency f and
therefore a relationship between m and f. Genetic drift was ignored
since it should not modify the expected value of f. Also, for
simplicity, mutations were assumed to have independent fitness
effects (no epistasis) and back mutations were ignored, which
seems reasonable in the short-term, because single forward
mutations will greatly outnumber secondary and back mutations.
Simulations were performed using Wolfram Mathematica and
Excel. A graphical representation of this correction can be found
in a previous work [2].
Analysis of published molecular evolutionary rates
In a previous meta-analysis, we collected evolutionary rate
estimates that were originally inferred from field isolates using
Bayesian analysis of dated sequences after validation of the
molecular clock [69]. Here, we used 170 of these estimates, which
corresponded to 62 different riboviruses. We sought to compare
viruses transmitted directly through respiratory secretions, blood,
sexual contact, feces, or animal bites (n = 113) against arboviruses
(n = 57). We used a two-way ANOVA in which the following
factors were included: transmission mode (fixed), viral family
(random) to account for phylogenetic relatedness, and sampling
timespan (covariate) to account for the known time-dependency of
evolution rate estimates. Since rates ranged several orders of
magnitude log-transformed data were used.
Supporting Information
Text S1 Detailed information of fluctuation test results for wild-
type MEFs (Table S1), p532/2 MEFs (Table S2), CT26 colon
cancer cells (Table S3), Neuro-2a neuroblastoma cells (Table S4),
BHK-21 cells under hypoxia (Table S5), BHK-21 cells at 28uC
(Table S6), S2 cells (Table S7), in Sf21 cells (Table S8), and C6/36
cells (Table S9).
(PDF)
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